The published manuscript titled "Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia" is available online and appears in the February 25, 2021 issue of NEJM.
According to the text, KarXT demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo
Incidences of somnolence, weight gain and extrapyramidal symptoms were similar in KarXT and placebo treatment groups.
KarXT is in Phase 3 clinical development for the treatment of psychosis in adults with schizophrenia.
KarXT, a proprietary oral modulator of muscarinic cholinergic receptors, is Karuna's lead product candidate. It combines xanomeline, a novel muscarinic agonist, with trospium, an FDA-approved muscarinic antagonist that does not appreciably cross the blood-brain-barrier, to preferentially stimulate muscarinic receptors in the central nervous system.
This novel product candidate, if approved, has the potential to usher in a new treatment paradigm and dramatically impact patients with schizophrenia and other psychotic disorders by providing a differentiated mechanism of action relative to current D2 dopamine and serotonin receptor-targeting antipsychotic drugs.
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver medicines for people living with psychiatric and neurological conditions.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT